|
private:ceresnanosciences
|
1749158
|
May 23rd, 2019 12:00AM
|
Ceres Nanosciences, Inc.
|
295
|
27.00
|
Open
|
Biotechnology
|
May 23rd, 2019 12:42PM
|
May 23rd, 2019 12:42PM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
Open
|
Clinical Diagnostics, Enhanced Sample Preparation, Biomarker Discovery and Validation, Sample Preservation
|
Open
|
|
MANASSAS
|
Virginia
|
US
|
20110
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 17th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 16th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 15th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 14th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 13th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 12th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 11th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 10th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|
|
private:ceresnanosciences
|
1749158
|
Feb 9th, 2018 12:00AM
|
Ceres Nanosciences, Inc.
|
192
|
14.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology.
The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs.
Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.
|
|
|
|
|
|
|
|
|
|
Ceres Nanosciences
|
|
|